Epidemiology and etiology of diffuse large B-cell lymphoma

Wang, Sophia S.

doi:10.1053/j.seminhematol.2023.11.004

Cited by 9 publications

(7 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diffuse Large B‐cell lymphoma (DLBCL), a highly aggressive form of non‐Hodgkin lymphoma (NHL), is the most common lymphoid cancer in adults 146 . It accounts for approximately one‐third of all NHL cases, with the percentage varying from 20% to 50%, depending on the country 147 . Among DLBCL cases, approximately 10% are EBV‐positive and often occur in immunocompromised individuals, such as HIV/AIDS patients and organ transplant recipients 148,149 .…”

Section: Roles Of Cerna Network and Virus‐related Cancersmentioning

confidence: 99%

Hijacking and rewiring of host CircRNA/miRNA/mRNA competitive endogenous RNA (ceRNA) regulatory networks by oncoviruses during development of viral cancers

Kamali,

Salehi,

Mostafavi

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

A significant portion of human cancers are caused by oncoviruses (12%–25%). Oncoviruses employ various strategies to promote their replication and induce tumourigenesis in host cells, one of which involves modifying the gene expression patterns of the host cells, leading to the rewiring of genes and resulting in significant changes in cellular processes and signalling pathways. In recent studies, a specific mode of gene regulation known as circular RNA (circRNA)‐mediated competing endogenous RNA (ceRNA) networks has emerged as a key player in this context. CircRNAs, a class of non‐coding RNA molecules, can interact with other RNA molecules, such as mRNAs and microRNAs (miRNAs), through a process known as ceRNA crosstalk. This interaction occurs when circRNAs, acting as sponges, sequester miRNAs, thereby preventing them from binding to their target mRNAs and modulating their expression. By rewiring the host cell genome, oncoviruses have the ability to manipulate the expression and activity of circRNAs, thereby influencing the ceRNA networks that can profoundly impact cellular processes such as cell proliferation, differentiation, apoptosis, and immune responses. This review focuses on a comprehensive evaluation of the latest findings on the involvement of virus‐induced reprogramming of host circRNA‐mediated ceRNA networks in the development and pathophysiology of human viral cancers, including cervical cancer, gastric cancer, nasopharyngeal carcinoma, Kaposi's sarcoma, hepatocellular carcinoma, and diffuse large B cell lymphoma. Understanding these mechanisms can improve our knowledge of how oncoviruses contribute to human tumourigenesis and identify potential targets for developing optimised therapies and diagnostic tools for viral cancers.

show abstract

Section: Roles Of Cerna Network and Virus‐related Cancersmentioning

confidence: 99%

Hijacking and rewiring of host CircRNA/miRNA/mRNA competitive endogenous RNA (ceRNA) regulatory networks by oncoviruses during development of viral cancers

Kamali,

Salehi,

Mostafavi

et al. 2024

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…1.2.1. Diffuse Large B Cell Lymphoma (DLBCL) DLBCL is the most common subtype of NHL and is known to be an aggressive lymphoma, representing approximately 30-40% of cases with an incidence rate of 7.2 per 100,000 individuals, and involving both nodal and extranodal sites [22,23]. Median age of diagnosis is 70 years [24].…”

Section: B Cell Lymphomasmentioning

confidence: 99%

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Jiménez,

Garrote-de-Barros,

López-Portugués

et al. 2024

IJMS

View full text Add to dashboard Cite

The maturation of B cells is a complex, multi-step process. During B cell differentiation, errors can occur, leading to the emergence of aberrant versions of B cells that, finally, constitute a malignant tumor. These B cell malignancies are classified into three main groups: leukemias, myelomas, and lymphomas, the latter being the most heterogeneous type. Since their discovery, multiple biological studies have been performed to characterize these diseases, aiming to define their specific features and determine potential biomarkers for diagnosis, stratification, and prognosis. The rise of advanced -omics approaches has significantly contributed to this end. Notably, proteomics strategies appear as promising tools to comprehensively profile the final molecular effector of these cells. In this narrative review, we first introduce the main B cell malignancies together with the most relevant proteomics approaches. Then, we describe the core studies conducted in the field and their main findings and, finally, we evaluate the advantages and drawbacks of flow cytometry, mass cytometry, and mass spectrometry for the profiling of human B cell disorders.

show abstract

“…DLBCL can arise de novo or as a transformation from a low-grade B cell lymphoma. The median age at diagnosis is in the mid-60s and identified rick factors include family history, several genetic susceptibility loci, viral infections (for instance EBV, HIV, HHV8, HBV, and HCV), solid-organ transplantation, autoimmune disorders, immunodeficiency, increased body mass index, pesticides, and ionizing radiation [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas

D’Alò,

Bellesi,

Maiolo

et al. 2024

Cancers

View full text Add to dashboard Cite

Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients’ chance of being cured and clinicians’ therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies.

show abstract

Epidemiology and etiology of diffuse large B-cell lymphoma

Cited by 9 publications

References 139 publications

Hijacking and rewiring of host CircRNA/miRNA/mRNA competitive endogenous RNA (ceRNA) regulatory networks by oncoviruses during development of viral cancers

Hijacking and rewiring of host CircRNA/miRNA/mRNA competitive endogenous RNA (ceRNA) regulatory networks by oncoviruses during development of viral cancers

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas

Contact Info

Product

Resources

About